Cargando…
Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion
Tuberous sclerosis complex (TSC) is characterized by tumor development in the brain, heart, kidney, and lungs. In TSC tumors, loss of the TSC1/TSC2 protein complex leads to activation of mTORC1 with downstream effects on anabolism and cell growth. Because mTORC1 activation enhances mRNA transcriptio...
Autores principales: | Zarei, Mahsa, Du, Heng, Nassar, Amin H., Yan, Rachel E., Giannikou, Krinio, Johnson, Sneha H., Lam, Hilaire C., Henske, Elizabeth P., Wang, Yubao, Zhang, Tinghu, Asara, John, Kwiatkowski, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829598/ https://www.ncbi.nlm.nih.gov/pubmed/31506280 http://dx.doi.org/10.1084/jem.20190251 |
Ejemplares similares
-
MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61
por: Zarei, Mahsa, et al.
Publicado: (2020) -
Notch transactivates Rheb to maintain the multipotency of TSC-null cells
por: Cho, Jun-Hung, et al.
Publicado: (2017) -
Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development
por: Giannikou, Krinio, et al.
Publicado: (2016) -
Spectrum of germline and somatic mitochondrial DNA variants in Tuberous Sclerosis Complex
por: Giannikou, Krinio, et al.
Publicado: (2023) -
Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations
por: Bongaarts, Anika, et al.
Publicado: (2017)